JP7728560B2 - 新規免疫調節小分子 - Google Patents

新規免疫調節小分子

Info

Publication number
JP7728560B2
JP7728560B2 JP2020571384A JP2020571384A JP7728560B2 JP 7728560 B2 JP7728560 B2 JP 7728560B2 JP 2020571384 A JP2020571384 A JP 2020571384A JP 2020571384 A JP2020571384 A JP 2020571384A JP 7728560 B2 JP7728560 B2 JP 7728560B2
Authority
JP
Japan
Prior art keywords
composition
compound
compounds
tlr4
formulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020571384A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021535080A (ja
JP2021535080A5 (https=
JPWO2020010090A5 (https=
Inventor
スチスミタ アチャリャ
プラニャ ダス
ビーモン アガルワル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ayuvis Research Inc
Original Assignee
Ayuvis Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ayuvis Research Inc filed Critical Ayuvis Research Inc
Publication of JP2021535080A publication Critical patent/JP2021535080A/ja
Publication of JP2021535080A5 publication Critical patent/JP2021535080A5/ja
Publication of JPWO2020010090A5 publication Critical patent/JPWO2020010090A5/ja
Priority to JP2023077029A priority Critical patent/JP2023109826A/ja
Application granted granted Critical
Publication of JP7728560B2 publication Critical patent/JP7728560B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/22—Cyclohexane rings, substituted by nitrogen atoms
    • C07H15/222—Cyclohexane rings substituted by at least two nitrogen atoms
    • C07H15/226—Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
JP2020571384A 2018-07-02 2019-07-02 新規免疫調節小分子 Active JP7728560B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023077029A JP2023109826A (ja) 2018-07-02 2023-05-09 新規免疫調節小分子

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862693023P 2018-07-02 2018-07-02
US62/693,023 2018-07-02
US16/460,211 US11364253B2 (en) 2018-07-02 2019-07-02 Immunodulating small molecules
US16/460,211 2019-07-02
PCT/US2019/040313 WO2020010090A1 (en) 2018-07-02 2019-07-02 Novel immunodulating small molecules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023077029A Division JP2023109826A (ja) 2018-07-02 2023-05-09 新規免疫調節小分子

Publications (4)

Publication Number Publication Date
JP2021535080A JP2021535080A (ja) 2021-12-16
JP2021535080A5 JP2021535080A5 (https=) 2022-03-16
JPWO2020010090A5 JPWO2020010090A5 (https=) 2022-03-16
JP7728560B2 true JP7728560B2 (ja) 2025-08-25

Family

ID=69060166

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020571384A Active JP7728560B2 (ja) 2018-07-02 2019-07-02 新規免疫調節小分子
JP2023077029A Pending JP2023109826A (ja) 2018-07-02 2023-05-09 新規免疫調節小分子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023077029A Pending JP2023109826A (ja) 2018-07-02 2023-05-09 新規免疫調節小分子

Country Status (8)

Country Link
US (1) US11364253B2 (https=)
JP (2) JP7728560B2 (https=)
KR (1) KR20210027381A (https=)
AU (1) AU2019297321B2 (https=)
BR (1) BR112020026989A2 (https=)
CA (1) CA3103503A1 (https=)
MX (1) MX2020014087A (https=)
WO (1) WO2020010090A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220143059A1 (en) * 2016-03-30 2022-05-12 Ayuvis Research, Inc. Compositions and therapeutic methods
US12594286B2 (en) 2018-07-02 2026-04-07 Ayuvis Research, Inc. Immunodulating small molecules
US20220241306A1 (en) * 2021-02-04 2022-08-04 Ayuvis Research, Inc. Chitin analogs for the treatment of kidney diseases
US12440471B2 (en) * 2021-07-30 2025-10-14 Ayuvis Research, Inc. Compositions and methods for the treatment of bronchopulmonary dysplasia (BPD) and BPD-associated pulmonary hypertension
CA3237508A1 (en) * 2021-11-12 2023-05-19 Suchismita ACHARYA Novel compositions and therapeutic methods
CA3257177A1 (en) * 2022-05-25 2023-11-30 Ayuvis Research, Inc. NEW SMALL IMMUNOMOLATORY MOLECULES
WO2024220628A1 (en) * 2023-04-18 2024-10-24 The Regents Of The University Of Colorado, A Body Corporate Target for combatting the foreign body response to implantable biomaterials
US20250332183A1 (en) * 2024-04-30 2025-10-30 Ayuvis Research, Inc. Compositions and methods for the stimulation of intermediate macrophages and treatments therewith

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017173024A1 (en) 2016-03-30 2017-10-05 AyuVis Research LLC Novel compositions and therapeutic methods

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3931319A (en) 1974-10-29 1976-01-06 Millmaster Onyx Corporation Capped polymers
US4027020A (en) 1974-10-29 1977-05-31 Millmaster Onyx Corporation Randomly terminated capped polymers
US4525346A (en) 1981-09-28 1985-06-25 Alcon Laboratories, Inc. Aqueous antimicrobial ophthalmic solutions
US4407791A (en) 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US4404365A (en) * 1981-12-28 1983-09-13 American Cyanamid Company Modulators of the complement system
US4836986A (en) 1984-09-28 1989-06-06 Bausch & Lomb Incorporated Disinfecting and preserving systems and methods of use
US4621075A (en) 1984-11-28 1986-11-04 The Procter & Gamble Company Gel-form topical antibiotic compositions
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
ES2037072T3 (es) 1986-12-19 1993-06-16 Duphar International Research B.V Suspension coadyuvante estabilizada que comprende bromuro de dimetil-dioctadecil-amonio.
EP0283085B1 (en) 1987-03-17 1992-11-11 Akzo N.V. Adjuvant mixture
US5037647A (en) 1988-09-15 1991-08-06 Alcon Laboratories, Inc. Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride
US5145643A (en) 1990-01-05 1992-09-08 Allergan, Inc. Nonoxidative ophthalmic compositions and methods for preserving and using same
US5300287A (en) 1992-11-04 1994-04-05 Alcon Laboratories, Inc. Polymeric antimicrobials and their use in pharmaceutical compositions
US5736522A (en) * 1993-11-15 1998-04-07 Kureha Chemical Industry Co., Ltd. Esculetin derivatives and method for manufacture thereof, use thereof, and pharmaceutical composition
AU7484198A (en) 1997-05-12 1998-12-08 Sage Pharmaceuticals, Inc. Topical spray for burn treatment and anti-infection
ATE265218T1 (de) * 2000-08-10 2004-05-15 Ocean Nutrition Canada Ltd Chlorella zubereitungen mit immunmodulatorischen eigenschaften
WO2005115336A2 (en) 2004-05-15 2005-12-08 Collegium Pharmaceutical, Inc. Sprayable formulations for the treatment of acute inflammatory skin conditions
JP2010502766A (ja) * 2006-06-16 2010-01-28 フロリダ アトランティック ユニヴァーシティ アジュバントとしてのキチン微粒子
EP3240411A4 (en) * 2014-11-12 2019-02-20 Tumorend LLC COMPOSITIONS, METHODS AND TREATMENTS FOR INHIBITING CELL ADHESION AND VIRUS BINDING AND PENETRATION

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017173024A1 (en) 2016-03-30 2017-10-05 AyuVis Research LLC Novel compositions and therapeutic methods

Also Published As

Publication number Publication date
JP2021535080A (ja) 2021-12-16
WO2020010090A1 (en) 2020-01-09
KR20210027381A (ko) 2021-03-10
AU2019297321B2 (en) 2022-02-03
CA3103503A1 (en) 2020-01-09
AU2019297321A1 (en) 2021-02-18
JP2023109826A (ja) 2023-08-08
US20200022995A1 (en) 2020-01-23
US11364253B2 (en) 2022-06-21
MX2020014087A (es) 2021-04-12
BR112020026989A2 (pt) 2021-03-30

Similar Documents

Publication Publication Date Title
JP7728560B2 (ja) 新規免疫調節小分子
Guo et al. Folate-modified triptolide liposomes target activated macrophages for safe rheumatoid arthritis therapy
JP5425642B2 (ja) 合成ｔｌｒアゴニストの結合体およびそのための使用
JP7357364B2 (ja) 新規組成物及び治療方法
WO2009099650A2 (en) Treatment of bladder diseases with a tlr7 activator
JP5889797B2 (ja) ランゲルハンス細胞の免疫抑制を逆転させる方法
CN112638414B (zh) 免疫调节小分子
US12594286B2 (en) Immunodulating small molecules
AU2023276287A1 (en) Novel immunodulating small molecules
HK40042187B (en) Immunomodulating compositions comprising oligosaccharide derivatives
HK40042187A (en) Immunomodulating compositions comprising oligosaccharide derivatives
AU2022383860A1 (en) Novel compositions and therapeutic methods
Collier Formulation and Characterization of Carrier Vehicles for Infectious Disease Treatment and Modulation of the Innate Immune System
HK40004181A (en) Beta-anomer-saccharides for use in the treatment of sepsis, septic shock, septicemia, burn or wound infection
HK40004181B (en) Beta-anomer-saccharides for use in the treatment of sepsis, septic shock, septicemia, burn or wound infection

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220308

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220509

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220728

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221108

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230509

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230516

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230623

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250408

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250805

R150 Certificate of patent or registration of utility model

Ref document number: 7728560

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150